Drug intelligence / Profile preview

Homo 16 D

Development stage: Unknown
Lead developer: Sinsan Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

**Homo 16 D** is an oral fixed-dose nutritional and neuroprotective tablet marketed by Sinsan Pharmaceuticals for support in **diabetic neuropathy**, vitamin D deficiency, and nutritional deficiencies. Each tablet contains methylcobalamin 1,500 mcg, alpha-lipoic acid 100 mg, folic acid 1.5 mg, pyridoxine hydrochloride 3 mg, and cholecalciferol 1,000 IU. Alpha-lipoic acid provides antioxidant support intended to reduce oxidative stress associated with peripheral nerve injury, while methylcobalamin, folate, pyridoxine, and vitamin D3 support vitamin repletion, neuronal function, and metabolic health.

Brand names: Homo 16 DHomo16 DHomo-16 D
Other names: HOMO 16DHOMO16DHOMO-16DHOMO-16 DHOMO16 DHOMO 16 D

Targets

MTR (Methionine synthase)VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Homo 16 D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homo 16 D.

Explore the full profile